Confounding effects of benign lung diseases on non-small cell lung cancer serum biomarker discovery

Clinical Proteomics

Volumn 5, Issue 3-4, 2009, Pages 148-155

  Rathinam, Sridhar ^a   Alzetani, Aiman ^a   Starczynski, Jane ^a   Rajesh, Pala B ^a   Nyangoma, Stephen ^b   Wakelam, Michael J O ^b   James, Nicholas D ^b,c   Wei, Wenbin ^b   Billingham, Lucinda J ^b   Johnson, Philip J ^b   Martin, Ashley ^b   Ward, Douglas G ^b  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Biomarker; Lung cancer; Proteomics; SELDI; Serum

Indexed keywords

BIOLOGICAL MARKER; PROTEOME;

ADULT; AGED; ARTICLE; BENIGN TUMOR; BIOASSAY; CANCER PATIENT; CONFOUNDING VARIABLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE FREE INTERVAL; FEMALE; HUMAN; IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN MICROARRAY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SERODIAGNOSIS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; VALIDATION PROCESS;

EID: 72949103721     PISSN: 15426416     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12014-009-9033-4     Document Type: Article

References (32)

1. DM Parkin, et al. 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 2 74 108 10.3322/canjclin.55.2.74 15761078
2. CF Mountain 2000 The international system for staging lung cancer Semin Surg Oncol 18 106 115 10.1002/(SICI)1098-2388(200003)18:2<106::AID-SSU4>3. 0.CO;2-P 10657912 1:STN:280:DC%2BD3c7is1emtw%3D%3D (Pubitemid 30090451)
3. JC Nesbitt, et al. 1995 Survival in early-stage non-small cell lung cancer Ann Thorac Surg 60 466 472 10.1016/0003-4975(95)00169-L 7646126 1:STN:280:DyaK2MznsVWisA%3D%3D
4. EF Petricoin, et al. 2002 Serum proteomic patterns for detection of prostate cancer J Natl Cancer Inst 94 20 1576 1578 12381711 1:CAS:528: DC%2BD38XovFSrurs%3D
5. TCW Poon, et al. 2003 Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes Clin Chem 49 5 752 760 10.1373/49.5.752 12709366 1:CAS:528:DC%2BD3sXjsVahs7Y%3D (Pubitemid 36513254)
6. DG Ward, et al. 2006 HCC induced changes in the serum proteome of hepatitis C infected chronic liver disease patients Br J Cancer 94 2 287 292 10.1038/sj.bjc.6602923 16404431 1:CAS:528:DC%2BD28XmvVygug%3D%3D (Pubitemid 43151549)
7. DG Ward, et al. 2006 Identification of serum biomarkers for colon cancer by proteomic analysis Br J Cancer 94 12 1898 1905 10.1038/sj.bjc.6603188 16755300 1:CAS:528:DC%2BD28XlsFequ7w%3D (Pubitemid 43882582)
8. S-Y Yang, et al. 2005 Application of serum SELDI proteomic patterns in diagnosis of lung cancer BMC Cancer. 5 83 10.1186/1471-2407-5-83 16029516 1:CAS:528:DC%2BD2MXpsFGqsrs%3D (Pubitemid 41461050)
9. Z Zhang, et al. 2004 Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer Cancer Res 64 5882 5890 10.1158/0008-5472.CAN-04-0746 15313933 1:CAS:528:DC%2BD2cXmslaks7Y%3D (Pubitemid 39095590)
10. J Au, et al. 2007 Deep proteome profiling of sera from never-smoked lung cancer patients Biomed Pharmacother 61 9 570 577 10.1016/j.biopha.2007.08.017 17913442 1:CAS:528:DC%2BD2sXhtF2ru7rI (Pubitemid 47562695)
11. S Dai, et al. 2007 Discovery and identification of serum amyloid a protein elevated in lung cancer serum Sci China C Life Sci 50 3 305 311 10.1007/s11427-007-0053-x 17609886 1:CAS:528:DC%2BD2sXosF2iu78%3D (Pubitemid 47036741)
12. K Han, et al. 2008 Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry Am J Clin Oncol 31 2 133 139 10.1097/COC.0b013e318145b98b 18391596 1:CAS:528:DC%2BD1cXltVGksL4%3D
13. X Xiao, et al. 2003 A preliminary analysis of non-small cell lung cancer biomarkers in serum Biomed Environ Sci 16 2 140 148 12964787
14. M Han, et al. 2008 Detection and significance of serum protein markers of small-cell lung cancer J Clin Lab Anal. 22 2 131 137 10.1002/jcla.20230 18348318 1:CAS:528:DC%2BD1cXmtFymtrg%3D (Pubitemid 351543945)
15. P Yildiz, et al. 2007 Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer J Thorac Oncol 2 10 893 901 10.1097/JTO.0b013e31814b8be7 17909350 (Pubitemid 47511591)
16. F Taguchi, et al. 2007 Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study J Natl Cancer Inst 99 11 838 846 10.1093/jnci/djk195 17551144 1:CAS:528:DC%2BD2sXns1als7o%3D
17. D Ward, et al. 2006 Preclinical and post-treatment changes in the HCC-associated serum proteome Br J Cancer 95 1379 1383 10.1038/sj.bjc.6603429 17060939 1:CAS:528:DC%2BD28XhtF2ns7%2FM (Pubitemid 44760089)
18. N Escher, et al. 2007 Posttranslational modifications of transthyretin are serum markers in patients with mycosis fungoides Neoplasia 9 3 254 259 10.1593/neo.06805 17401465 1:CAS:528:DC%2BD2sXktVarur4%3D (Pubitemid 46457242)
19. J Koopmann, et al. 2004 Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry Clin Cancer Res 10 860 868 10.1158/1078-0432.CCR-1167-3 14871961 1:CAS:528: DC%2BD2cXhtFCns7o%3D (Pubitemid 38198884)
20. N Munro, et al. 2006 Urinary biomarker profiling in transitional cell carcinoma Int J Cancer 116 11 2642 2650 10.1002/ijc.22238 1:CAS:528: DC%2BD28XhtFygur7I (Pubitemid 44691320)
21. C Scarlett, et al. 2006 Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture Hepatology 44 3 658 666 10.1002/hep.21294 16941699 1:CAS:528:DC%2BD28XhtVeqt7nE (Pubitemid 44433722)
22. JM Koomen, et al. 2005 Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins Clin Cancer Res 11 1110 1118 15709178 1:CAS:528:DC%2BD2MXht1ynt7w%3D
23. J Peng, et al. 2009 Using the protein chip interface with quadrupole time-of-flight mass spectrometry to directly identify peaks in SELDI profiles-initial evaluation using low molecular weight serum peaks Proteomics 9 2 492 498 10.1002/pmic.200800424 19142938 1:CAS:528:DC%2BD1MXhvVSisLY%3D
24. D Ward 2008 et al Proteomic profiling of urine for the detection of colon cancer. 6 19 10.1186/1477-5956-6-19 (Pubitemid 351935851)
25. D Ward, et al. 2008 SELDI-TOF-MS determination of hepcidin in clinical samples using stable isotope labelled hepcidin as an internal standard Proteome Sci 6 28 10.1186/1477-5956-6-28 18854031 1:CAS:528:DC%2BD1cXhtlahur%2FE
26. K Kozak, et al. 2005 Characterization of serum biomarkers for detection of early stage ovarian cancer Proteomics 5 17 4589 4596 10.1002/pmic.200500093 16237736 1:CAS:528:DC%2BD2MXht12nt7vN (Pubitemid 41739936)
27. L Miguet, et al. 2006 Discovery and identification of potential biomarkers in a prospective study of chronic lymphoid malignancies using SELDI-TOF-MS J Proteome Res 5 9 2258 2269 10.1021/pr060058y 16944938 1:CAS:528:DC%2BD28Xnsl2rurY%3D (Pubitemid 44330819)
28. L Liu, et al. 2007 Reduced transthyretin expression in sera of lung cancer Cancer Sci 98 10 1617 1624 10.1111/j.1349-7006.2007.00576.x 17683510 1:CAS:528:DC%2BD2sXhtF2qtbzN (Pubitemid 47308460)
29. L Allard, et al. 2004 ApoC-I and ApoC-III as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke Proteomics 4 8 2242 2251 10.1002/pmic.200300809 15274118 1:CAS:528:DC%2BD2cXmsFekt7o%3D (Pubitemid 39025324)
30. ET Fung, et al. 2005 Classification of cancer types by measuring variants of host response proteins using SELDI serum assays Int J Cancer 115 783 789 10.1002/ijc.20928 15704152 1:CAS:528:DC%2BD2MXkvF2ksLw%3D (Pubitemid 40776702)
31. J Song, et al. 2006 Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by surface-enhanced laser desorption/ionization-based immunoassay Clin Chem 52 6 1045 1053 10.1373/clinchem.2005.065722 16574760 1:CAS:528:DC%2BD28XltlSrtb4%3D (Pubitemid 43794416)
32. J Villanueva, et al. 2006 Differential exoprotease activities confer tumor-specific serum peptidome patterns J Clin Invest 116 1 271 284 10.1172/JCI26022 16395409 1:CAS:528:DC%2BD28XjslOgtQ%3D%3D (Pubitemid 43121812)